Why Choose Stiripentol Over Fenfluramine for Dravet Syndrome?
Stiripentol suits patients with Dravet syndrome who need an add-on therapy without cardiac monitoring, as it lacks fenfluramine's cardiovascular risks like valvular heart disease and pulmonary hypertension. Approved for ages 2+ in combination with clobazam and valproate, it reduces seizure frequency via allosteric modulation of GABAA receptors and CYP450 inhibition, boosting clobazam levels.[1][2]
Key Mechanism Differences
Stiripentol acts as a positive allosteric modulator at GABAA receptors, enhancing GABAergic inhibition, and inhibits CYP2C19/3A4 to increase clobazam exposure—key for refractory cases. Fenfluramine releases serotonin and inhibits vesicular monoamine transporters, reducing seizures but requiring echocardiograms every 6 months due to appetite suppression and cardiac effects.[3][4]
Patient Groups Where Stiripentol Fits Better
- Cardiac concerns: Ideal for those with heart conditions or family history; fenfluramine carries black-box warnings for valvular issues seen in trials (up to 12% incidence).[2][5]
- Weight or appetite issues: No significant appetite loss, unlike fenfluramine's 20-30% body weight reduction, suiting underweight kids.[6]
- No monitoring burden: Oral capsules/powder, dosed by weight; no routine heart scans needed.[1]
Fenfluramine edges out in flexibility (ages 2+, monotherapy possible) and faster onset in some trials, but stiripentol avoids long-term cardiac surveillance.[4]
Side Effect Profiles Compared
| Aspect | Stiripentol | Fenfluramine |
|--------|-------------|--------------|
| Common | Sedation (33%), loss of appetite (25%), weight gain | Decreased appetite (45%), diarrhea (25%), fatigue |
| Serious | Agitation, insomnia (less frequent) | Valvular heart disease (monitor required), hypertension |
| Dropouts in trials | 7-14% due to sedation | 10-15% due to GI/cardiac issues[2][5][7] |
Stiripentol causes less GI distress but more sedation, often manageable by lowering clobazam.[1]
Dosing and Practical Considerations
Stiripentol: 50 mg/kg/day split BID/TID, max 3g/day; titrate over 2 weeks. Fenfluramine: 0.4 mg/kg/day max, liquid oral solution. Stiripentol needs fat-rich meals for absorption; both interact with CYP inducers.[3][8]
Trial Data Head-to-Head Insights
In Dravet studies, stiripentol dropped seizures 50-70% vs. placebo; fenfluramine 60-75%. No direct comparator trials, but real-world data favor stiripentol for cardiac-risk patients.[9][10] Guidelines (NICE, AAN) recommend both as add-ons, prioritizing based on tolerability.[11]
Sources
[1]: FDA Label - Diacomit (Stiripentol)
[2]: FDA Label - Fintepla (Fenfluramine)
[3]: Chiron et al., Epilepsia 2007
[4]: Lagae et al., Lancet Neurol 2018
[5]: Zixis et al., Epilepsia 2021
[6]: Post-marketing safety data, EMA
[7]: NCT00748923 (Stiripentol trial)
[8]: NCT02823191 (Fenfluramine trial)
[9]: Coppola et al., Epilepsy Behav 2020
[10]: Specchio et al., Neurology 2022
[11]: NICE Guideline NG217